Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Agilent Technologies introduced SureFISH ALK, ROS1, and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization products. The probes are repeat-free, able to target specific sequences of interest, and use high-fidelity oligos designed in silico.
March 2014—Waters Corp. announced three UNIFI Scientific Information System solutions: Waters Glycan Application Solution with UNIFI, Forensic Toxicology Screening Application Solution with UNIFI, and Natural Products Application Solution with UNIFI. Each application features a proprietary, comprehensive library of relevant molecules.
March 2014—Agilent Technologies introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin-fixed paraffin-embedded tissue samples.
March 2014—Medical Chemical’s Total-Fix stool fixative for ova and parasites is now patented. Total-Fix does not contain any mercury, formaldehyde, or PVA. It is a multi-use, single-vial system that preserves stool specimens for staining (Trichrome/iron hematoxylin), concentration, Giardia and Cryptosporidium antigens, and fluorescent assays. Total-Fix also preserves molecular material in stool for molecular (real PCR) assays.
March 2014—Qiagen expanded its strategic partnership with Exosome Diagnostics to develop a noninvasive molecular in vitro diagnostic. The novel blood-based diagnostic detects certain mutations of an undisclosed gene associated with non-small cell lung cancer and other malignancies and has the potential to be paired with several new anticancer therapeutics.
March 2014—Beckman Coulter Diagnostics received FDA 510(k) clearance for its Access Total βhCG (5th IS) assay, the first βhCG assay standardized to the highly purified World Health Organization 5th International Standard (IS) for chorionic gonadotropin.
March 2014—The Tosoh G8 (Tosoh Automated Glycohemoglobin Analyzer HLC-723G8) has been cleared by the FDA as the first high-performance liquid chromatography (HPLC) instrument for use as an aid in diagnosing diabetes and identifying patients who may be at risk for developing diabetes. The Tosoh G8 was initially cleared in 2008 as a diabetes monitoring device; the intended use has now been expanded to screening as well.
March 2014—Audit MicroControls added the Linearity FD D-Dimer PathFast Immunoanalyzer, five levels, to its line of calibration verification/linearity products. It is intended to simulate human patient serum samples for the purpose of determining linearity, calibration verification, and verification of reportable range for D-dimer.
March 2014—Israeli scientist Michael Yartsev, PhD, CV Starr postdoctoral research fellow of the Princeton Neuroscience Institute at Princeton University, won the 2013 Eppendorf & Science Prize for Neurobiology. Dr. Yartsev uses an unusual animal model—the bat—to study the underlying neural mechanisms of spatial memory and navigation in the mammalian brain.
March 2014—The Center for Phlebotomy Education will conduct intensive three-day seminars in Indianapolis and San Francisco for those who train or manage phlebotomists. The event will provide strategies to help attendees reduce expenses by cultivating satisfied, long-term employees; cut costs through process improvement; nurture professionalism and responsibility among specimen-collection personnel; implement different learning styles to maximize teaching; and mentor students and new staff.
